Scientists around the world are racing to develop an effective vaccine against COVID-19, the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Speaking to The Hindu, Suresh Jadhav, Executive Director of the Pune-based Serum Institute of India said the company will start manufacturing small quantities of the vaccine if the Phase-1 trial results are encouraging.
William met "guinea pigs" testing the vaccine which experts hope will beat the killer virus that has left more than 43,000 Brits dead.
China is seeking to trial potential vaccines overseas because of a lack of new patients at home.
Coronavirus vaccine alliance finds manufacturing capacity for 400 crore doses
Rates have since dropped, but a sufficient number of volunteers have to be exposed to the virus to see whether a vaccine protects them or not.
Various dosages and timings were tried. Meanwhile, Beijing-based China National Biotec Group Co. has received regulatory approval to conduct phase 3 trials of its Covid-19 vaccine in the UAE.
China's recombinant protein vaccine candidate has been jointly developed by the Institute of Micro－biology and Anhui Zhifei Longcom Biopharmaceutical.
The first person in the trial will have a second booster shot within four weeks, and several other subjects will be recruited in the coming days, according to Imperial, which plans to recruit 15 people into the trial in this first phase, and 300 in total. Common recombinant vaccines include those against hepatitis B, influenza, whooping cough and human papillomavirus or HPV.
Kathy, 39, who works in finance, was one of the first volunteers and she said she put herself forward because she wanted to play a part in fighting the virus.
Gel hydroalcoolique et soleil : attention danger !
Depuis plusieurs mois c'est devenu un réflexe: se désinfecter les mains au gel hydroalcoolique plusieurs fois par jour. A noter également qu'une utilisation intensive de gel hydroalcoolique peut irriter la peau.
As of Monday, the World Health Organization had recorded around 142 candidate vaccines in development around the globe, 13 of which have entered clinical trials. Trials of the Oxford vaccine also began this week in Brazil and South Africa.
"We are now poised to test the vaccine in the dose evaluation phase before moving forward to evaluating it in larger numbers".
Colin MacKay, CEO of Symbiosis, said, "With many years of direct experience manufacturing medicines and vaccines of this nature for clinical trials and commercial markets, we are delighted to be able to leverage our expertise and competitive strengths to accelerate the development of this vaccine for AZ and to add value to the project".
Monaco : Slimani et Bakayoko s'en vont (off.)
C'est le cas notamment de deux joueurs qui ont beaucoup joué cette saison: Tiémoué Bakayoko et Islam Slimani . Prêté par Chelsea , l'ancien milieu de terrain monégasque (2014-2017) a disputé 23 matches l'an dernier.